Protalix BioTherapeutics, Inc. (PLX)

1.1500 -0.0300 (-2.54%) At close: 04:00PM EDT

Protalix BioTherapeutics, Inc.

Science Park
2 Snunit St. POB 455
Karmiel 2161401
Israel
972 4 902 8100
https://www.protalix.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 208

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Dror Bashan	President, CEO & Director	473.16k	N/A	1967
Mr. Eyal Rubin M.B.A.	Senior VP, CFO, Treasurer & Corporate Secretary	813.73k	N/A	1976
Mr. Yaron Naos	Senior Vice President of Operations	409.95k	N/A	1964
Ms. Yael Fellous	Vice President of Human Resources	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Corporate governance

Protalix BioTherapeutics, Inc.’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 3; Board: 8; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.